Source-grounded facts extracted from Journey Medical Corp's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Journey Medical Corp amended term loan of $25.0 million with SWK Funding LLC maturing June 27, 2028.
“October 21, 2024 and the Third Amendment, the “Amended Credit Agreement”). The Amended Credit Agreement provides for a term loan facility in the original principal amount of $25.0 million. As of the date of this report, the Company has drawn the full $25.0 million, which is treated under the Amended Credit Agreement as a single loan (the “Term Loan”). The Third”
Journey Medical Corp: Fourth Amended and Restated Certificate of Incorporation filed to provide for officer exculpation (effective 2025-06-24).
“effective upon filing, to provide for, among other things, officer exculpation”
Ramsey Alloush was appointed as Chief Operating Officer at Journey Medical Corp.
“On April 1, 2025, Ramsey Alloush, the General Counsel of Journey Medical Corporation (the “ Company ”), was appointed as the Company’s Chief Operating Officer.”
Michael C. Pearce was appointed as Director at Journey Medical Corp.
“appointed Michael C. Pearce, age 62, to serve on the Board”
Journey Medical Corp reported first quarter ended March 31, 2024 results: revenue Total net product revenues were $13.0 million, net income Net loss was $10.4 million, EPS $(0.53) per share basic and diluted.
“New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues for the first quarter ended March 31, 2024 were $13.0 million, a 7% increase from the $12.2 million reported in the first quarter of 2023 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a”
Joseph Benesch was appointed as Chief Financial Officer at Journey Medical Corp.
“On April 26, 2024, the Board of Directors (the “ Board ”) of Journey Medical Corporation (the “ Company ”) appointed Joseph Benesch, age 57, as the Company’s permanent Chief Financial Officer.”
Journey Medical Corp reported the full year ended December 31, 2023 results: revenue $79.2 million, net income $(3.9) million, EPS $(0.21) per share basic and diluted.
“EXHIBIT 99.1 Exhibit 99.1 Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate Highlights Company generated total revenues of $79.2 million for the full year ended December 31, 2023, a 7% increase from the $73.7 million reported in 2022 Achieved $15.6 million in operating cost savings in 2023, ahead of initial”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.